期刊文献+

Quality Measurement and Improvement Study of Surgical Coronary Revascularization: Medication Adherence (MISSION-2)

Quality Measurement and Improvement Study of Surgical Coronary Revascularization: Medication Adherence (MISSION-2)
原文传递
导出
摘要 Background: Secondary preventive therapies play a key role in the prevention of adverse outcomes after coronary artery bypass grafting (CABG). However, medication adherence alter CABG is often poor, and conventional interventions for improving adherence have limited success. With increasing penetration of smartphones, health-related smartphone applications might provide an opportunity to improve adherence. Carefully designed trials are needed to provide reliable evidence for the use of these applications in patients after CABG. Methods: The Measurement and Improvement Studies of Surgical Coronary Revascularization: Medication Adherence (MISSION-2) study is a multicenter randomized controlled trial, aiming to randomize 1000 CABG patients to the intervention or control groups in a 1 : 1 ratio. We developed the multifaceted, patient-centered, smartphone-based Heart Health Application to encourage lnedication adherence in the intervention group through a health self management program initiated dnring hospital admission for CABG. The application integrated daily scheduled reminders to take the discharge medications, cardiac edticational materials, a dynamic dashboard to review cardiovascular risk factors and secondary prevention targets, and weekly questionnaires with interactive feedback. The primary outcome was secondary preventive medication adherence measured by the Chinese version of the 8-item Morisky Medication Adherence Scale at 6 months after randomization. Secondary outcomes included all-cause death, cardiovascular rehospitalization, and a composite of death, myocardial infarction, stroke, and repeat revascularization.Discussion: Findings will not only provide evidence regarding the feasibility and effectiveness of the described intervention for improving adherence to CABG secondary preventive therapies but also explore a model tor outpatient health self-managenlent that could be translated to various chronic diseases and widely disseminated across resource-limited settings. Background: Secondary preventive therapies play a key role in the prevention of adverse outcomes after coronary artery bypass grafting (CABG). However, medication adherence alter CABG is often poor, and conventional interventions for improving adherence have limited success. With increasing penetration of smartphones, health-related smartphone applications might provide an opportunity to improve adherence. Carefully designed trials are needed to provide reliable evidence for the use of these applications in patients after CABG. Methods: The Measurement and Improvement Studies of Surgical Coronary Revascularization: Medication Adherence (MISSION-2) study is a multicenter randomized controlled trial, aiming to randomize 1000 CABG patients to the intervention or control groups in a 1 : 1 ratio. We developed the multifaceted, patient-centered, smartphone-based Heart Health Application to encourage lnedication adherence in the intervention group through a health self management program initiated dnring hospital admission for CABG. The application integrated daily scheduled reminders to take the discharge medications, cardiac edticational materials, a dynamic dashboard to review cardiovascular risk factors and secondary prevention targets, and weekly questionnaires with interactive feedback. The primary outcome was secondary preventive medication adherence measured by the Chinese version of the 8-item Morisky Medication Adherence Scale at 6 months after randomization. Secondary outcomes included all-cause death, cardiovascular rehospitalization, and a composite of death, myocardial infarction, stroke, and repeat revascularization.Discussion: Findings will not only provide evidence regarding the feasibility and effectiveness of the described intervention for improving adherence to CABG secondary preventive therapies but also explore a model tor outpatient health self-managenlent that could be translated to various chronic diseases and widely disseminated across resource-limited settings.
出处 《Chinese Medical Journal》 SCIE CAS CSCD 2018年第12期1480-1489,共10页 中华医学杂志(英文版)
关键词 Coronary Artery Bypass Grafting MedicationAdherence Mobile Applications Mobile Health Secondary Prevention Coronary Artery Bypass Grafting MedicationAdherence Mobile Applications Mobile Health Secondary Prevention
  • 相关文献

参考文献2

二级参考文献43

  • 1胡盛寿,孔灵芝.中国心血管病报告2007.北京:中国大百科全书出版社,2007.2.
  • 2中华医学会心血管病学分会.中华心血管病杂志编辑委员会,慢性稳定性心绞痛诊断和治疗指南.中华心血管病杂志,2007,35(3):199-204.
  • 3World Health Organization. The global burden of disease: 2004 update. 2004. (Accseesd September 2011 at http://www, who.Int/healthinfo/global burden_disease/2004_report_update/en/index, html).
  • 4Hu SS, Kong LZ. Report on cardiovascular diseases in China (2007). Beijing, National Center for Cardiovascular Diseases, Encyclopedia of China Publishing House, 2008.
  • 5Center for of Health. survey in Science& Health Statistics and Information, China Ministry An analysis report of national health services 2003. Beijing, Chinese Academy of Medical Peking Union Medical College Pres, 2004.
  • 6Chinese Medical Association Ischemic Stroke Guidelines Working Group. Guidelines for secondary prevention of ischaemic stroke and transient ischaemic attack. Chin J Neuro[ (Chin) 2010; 43: 154-160.
  • 7Cholesterol Treatment Trialists' Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials ofstatins. I ,~neet v. hh~. "~6~,. 1 "~67- J "~TR.
  • 8Joint Committee for Developing Chinese Prevention and Treatment of Dyslipidemia in guidelines on prevention and treatment of adults. Chin J Cardiol (Chin) 2007: 35:390-4 Guidelines on Adults. Chinese dyslipidemia in 19.
  • 9Smith SC Jr, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol 2006; 47: 2130-2139.
  • 10Glader EL, Sjolander M, Eriksson M, Lundberg M. Persistent use of secondary preventive drugs declines rapidly during the first 2 years after stroke. Stroke 2010; 41: 397-401.

共引文献39

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部